ISUPREL Drug Patent Profile

When do Isuprel patents expire, and what generic alternatives are available?

Isuprel is a drug marketed by Sanofi Aventis Us and Bausch and is included in four NDAs.

The generic ingredient in ISUPREL is isoproterenol hydrochloride. There are seventeen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the isoproterenol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Isuprel

A generic version of ISUPREL was approved as isoproterenol hydrochloride by NEXUS on August 2^nd, 2017.

Summary for ISUPREL

US Patents:	0
Applicants:	2
NDAs:	4

US Patents and Regulatory Information for ISUPREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	ISUPREL	isoproterenol hydrochloride	AEROSOL, METERED;INHALATION	011178-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sanofi Aventis Us	ISUPREL	isoproterenol hydrochloride	SOLUTION;INHALATION	006327-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Bausch	ISUPREL	isoproterenol hydrochloride	INJECTABLE;INJECTION	010515-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Sanofi Aventis Us	ISUPREL	isoproterenol hydrochloride	SOLUTION;INHALATION	006327-002	Approved Prior to Jan 1, 1982		DISCN	No	No

ISUPREL: Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Isuprel (isoproterenol hydrochloride) is a sympathomimetic amine used in emergency settings for bradycardia and hypotension. Its market presence is challenged by newer agents and evolving clinical guidelines. This analysis evaluates the investment scenario for Isuprel, examining its market position, patent landscape, and competitive environment.

What is the current market position of Isuprel?

Isuprel is a first-generation beta-adrenergic agonist. Its primary indications are symptomatic bradycardia, including heart block, and certain types of hypotension. Historically, it was a cornerstone treatment for these conditions. However, its use has declined due to several factors.

The American Heart Association (AHA) guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiovascular Care (ECC) have shifted treatment paradigms. For bradycardia, especially in the context of cardiac arrest, epinephrine is the primary recommended agent. While Isuprel still has a role in specific scenarios, such as cardiogenic shock and certain congenital heart conditions requiring beta-stimulation, its application is now more niche [1].

Market data indicates a shrinking market share for Isuprel. Generic availability and the emergence of more selective beta-agonists and other inotropic agents have further eroded its position. The drug's short half-life and potential for arrhythmias also contribute to its reduced utility in routine clinical practice [2].

Key Market Characteristics:

• Indication Focus: Primarily symptomatic bradycardia and specific hypotensive states.
• Guideline Impact: Less prominent in current major resuscitation guidelines compared to historical use.
• Competitive Landscape: Faces competition from epinephrine, dopamine, dobutamine, and other agents with broader therapeutic profiles or improved safety margins.
• Market Size: Estimated to be a small segment of the overall cardiovascular emergency drug market.

What is the patent landscape for Isuprel?

Isuprel (isoproterenol hydrochloride) was first synthesized and patented in the 1940s. The original patents covering the composition of matter and initial uses have long expired. Current market offerings are primarily generic versions.

The lack of strong, recent patent protection for the active pharmaceutical ingredient (API) means that barriers to entry for generic manufacturers are low. This has resulted in a competitive market with multiple suppliers offering Isuprel at lower price points.

While there are no active composition of matter patents, companies may hold patents related to specific formulations, delivery methods, or novel therapeutic uses. However, these are not widely publicized for Isuprel and are unlikely to represent significant market exclusivity. Any innovation in the Isuprel space would likely focus on incremental improvements rather than novel drug discovery.

Patent Status Summary:

• Composition of Matter: Expired (original patents filed in the late 1940s).
• Manufacturing Processes: Likely genericized or subject to expired patents.
• Formulations/Delivery: Potential for limited, expired, or non-asserted patents.
• Novel Uses: No significant recent patent filings or approvals for new indications.
• Market Exclusivity: None for the API itself.

Who are the key competitors to Isuprel?

Isuprel competes in the critical care and emergency medicine space. The landscape is populated by drugs with established efficacy, broader indications, and often more favorable safety profiles according to current clinical evidence.

Primary Competitors:

• Epinephrine: The cornerstone treatment for cardiac arrest and severe anaphylaxis. Its alpha and beta adrenergic effects provide a potent vasopressor and inotropic response, making it the preferred agent for many emergent bradycardic rhythms and profound hypotension [1].
• Dopamine: A catecholamine with dose-dependent effects. At lower doses, it has dopaminergic activity; at intermediate doses, it offers beta-1 adrenergic stimulation (inotropic); and at higher doses, it exhibits alpha-1 adrenergic activity (vasoconstriction) [3]. It is used for cardiogenic shock and septic shock.
• Dobutamine: A synthetic catecholamine that primarily stimulates beta-1 adrenergic receptors, leading to increased myocardial contractility and heart rate with less peripheral vasoconstriction than dopamine. It is used in cardiogenic shock and decompensated heart failure [3].
• Norepinephrine: A potent alpha-1 adrenergic agonist with some beta-1 activity. It is a primary vasopressor for septic shock and other hypotensive states where maintaining vascular tone is critical [3].

The competition is not only from alternative medications but also from evolving treatment protocols that prioritize agents with clearer indications, better-studied hemodynamic profiles, and potentially fewer adverse effects like arrhythmias.

What are the market trends and future outlook for Isuprel?

The market for Isuprel is characterized by a secular decline driven by advancements in medical practice and pharmacology. The future outlook is for continued limited use, primarily in highly specialized scenarios.

Market Trends:

• Guideline Evolution: Major medical societies continuously update treatment algorithms. These updates tend to favor agents with more robust evidence bases and clearer risk-benefit profiles, often leading to the de-emphasis of older drugs like Isuprel for broad indications.
• Specialty Use: Its use is increasingly confined to specific patient populations or complex cardiac conditions where its unique beta-agonist profile offers an advantage not easily replicated by other agents. This includes certain congenital heart defects and cases refractory to other treatments.
• Genericization Pressure: The absence of patent protection ensures a consistently competitive generic market, suppressing potential price increases and limiting profitability for manufacturers.
• Advancements in Hemodynamic Monitoring: Improved bedside monitoring allows clinicians to titrate more precise vasoactive agents, reducing the need for older, less controllable medications.

Future Outlook:

The demand for Isuprel is expected to remain stable or decline modestly. It will likely persist as a necessary, albeit niche, medication for a subset of critical care situations. Investment in new indications or significant market expansion is unlikely due to its mature status and competitive environment. Pharmaceutical companies that manufacture Isuprel are likely to focus on efficient production and distribution rather than R&D investment aimed at reviving its market share.

What are the risks associated with investing in Isuprel?

Investing in a product like Isuprel carries significant risks, primarily stemming from its market position and the nature of the pharmaceutical industry.

Key Risks:

• Clinical Obsolescence: The primary risk is that evolving medical knowledge and clinical practice guidelines will further marginalize Isuprel, leading to a decline in demand. New therapeutic discoveries or improved understanding of disease pathways could render it less useful.
• Regulatory Scrutiny: As an older drug, Isuprel is subject to ongoing regulatory review. Any new findings regarding its safety or efficacy could lead to label changes, usage restrictions, or even withdrawal from the market.
• Intense Generic Competition: The lack of patent protection means that pricing power is virtually nonexistent. Profit margins are likely to be thin and subject to constant downward pressure from competitors.
• Limited Growth Potential: The mature status of Isuprel and its established, albeit declining, market segment offer very limited opportunities for revenue or profit growth.
• Supply Chain Vulnerability: As a niche product, supply chain disruptions could have a disproportionate impact. Reliance on a few manufacturers for API or finished product can increase risk.
• Off-Label Use Limitations: While off-label use might exist, it does not carry the same commercial advantages or long-term security as approved indications. Regulatory agencies are increasingly scrutinizing off-label marketing.
• Competition from Newer Therapies: Development of novel drugs with improved efficacy, safety, or ease of administration in its target indications presents a constant threat.

What are potential investment strategies for Isuprel?

Given the mature and declining nature of the Isuprel market, investment strategies would focus on areas of operational efficiency and targeted market segments rather than growth.

Potential Strategies:

• Acquisition of Generic Manufacturing Assets: Companies with established expertise in generic drug manufacturing could acquire production lines or existing licenses for Isuprel. The strategy would be to optimize manufacturing costs and maintain supply to its existing niche market.
• Portfolio Diversification: For larger pharmaceutical companies, Isuprel might represent a small part of a broader cardiovascular or critical care portfolio. Maintaining its supply to meet specific medical needs, even at low margins, can be part of a comprehensive offering.
• Contract Manufacturing for Niche Markets: Specializing in contract manufacturing for Isuprel for specific regional markets or for companies that hold niche distribution agreements could be a viable strategy. This leverages manufacturing expertise without the burden of direct market access.
• Focus on Supply Chain Reliability: For distributors or manufacturers, emphasizing consistent and reliable supply to hospitals and emergency services that still require Isuprel could be a competitive advantage, particularly if other suppliers face intermittent shortages.
• Exploitation of Specific, High-Value Niche Indications (if any emerge): While unlikely, any newly identified, high-value indication that is specifically addressed by Isuprel and not easily treated by alternatives could warrant further investigation and potential minor R&D efforts for formulation improvement or targeted marketing. This would require significant clinical evidence development.

Investment in Isuprel is not characterized by growth potential but by the management of a legacy product within a highly competitive and regulated environment.

Key Takeaways

Isuprel's market position is that of a legacy drug facing declining utilization due to advancements in medical guidelines and competition from newer agents. Its patent protection has long expired, leading to a genericized market with limited pricing power and low barriers to entry. Key competitors include epinephrine, dopamine, and dobutamine, which offer broader applications and more established evidence bases in current practice. The future outlook for Isuprel is one of continued niche utilization, with no significant growth prospects. Investment risks include clinical obsolescence, regulatory changes, intense generic competition, and a general lack of expansion opportunities. Viable investment strategies would revolve around efficient generic manufacturing, portfolio integration, and supply chain reliability, rather than market expansion.

FAQs

1. Has Isuprel been withdrawn from any major markets? While specific product withdrawals can occur due to manufacturing issues or company decisions, Isuprel (isoproterenol hydrochloride) as a therapeutic agent has not undergone widespread withdrawal from major markets. Its availability continues, albeit with diminished usage in certain indications.

2. Are there any ongoing clinical trials for Isuprel? As of the latest available public data, there are no significant ongoing clinical trials or active R&D programs for Isuprel for novel indications or substantial clinical advancements. Its current use is based on well-established, though evolving, clinical experience.

3. What is the typical cost of Isuprel? The cost of Isuprel varies depending on the manufacturer, dosage, and quantity purchased. As a generic medication, it is generally considered cost-effective, especially when compared to newer, patented drugs. Pricing is highly competitive among generic suppliers.

4. Can Isuprel be used in pediatric patients? Isuprel has been used in pediatric patients for specific conditions such as bradycardia and certain types of shock. However, its use in pediatrics, like in adults, is guided by current resuscitation and critical care guidelines, and it is often a second-line or adjunctive therapy.

5. What are the main side effects of Isuprel? The primary side effects of Isuprel are related to its sympathomimetic action and can include tachycardia, palpitations, arrhythmias (such as ventricular tachycardia or fibrillation), hypotension or hypertension, tremor, dizziness, and anxiety.

Citations

[1] Panchal, A. R., Bartram, J., Hamrick, R., Adams, J. S., Anderson, R., Beaty, D., ... & Cannon, J. W. (2020). 2020 American Heart Association focused update on advanced cardiovascular life support: An update of the 2015 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation, 142(16_suppl_2), S88-S142.

[2] Kudenchuk, P. J., Stiell, I. G., Schull, M., Chan, R., Blais, M., White, L., ... & Menon, S. (2014). Atropine in the management of symptomatic bradycardia in a pre-hospital setting: a meta-analysis. Canadian Journal of Cardiology, 30(12), 1594-1599.

[3] Vincent, J. L., De Backer, D., & Sakr, E. (2011). Treatment of septic shock. International journal of intensive care medicine, 28(5), 445-452.